With a return of 46 per cent year-to-date, the ACATIS Datini Valueflex is on a roll this year. The 10 per cent allocation to cryptos, via an investment in three crypto ETFs and a direct investment in Coinbase, have helped considerably. But at the top is vaccine maker BioNTech, which is responsible for 11 per cent of the return, according to a conversation with fund manager Hendrik Leber (pictured), who called the fund the “chilli pepper of an investment portfolio”.
Enregistrez-vous ou connectez-vous pour lire la suite. Investment Officer est une plateforme journalistique indépendante à destination des professionnels de l’industrie belge des investissements.
L’abonnement est GRATUIT pour les professionnels actifs au sein de banques et gestionnaires d’actifs indépendants.
